New drug cocktail aims to outsmart lung cancer resistance

NCT ID NCT04762199

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called MRX-2843 combined with the standard targeted therapy osimertinib in people with advanced EGFR-mutant non-small cell lung cancer. The goal is to find the safest dose and see if the combination can stop tumor growth by blocking key enzymes. About 69 participants will be enrolled to assess side effects and early signs of effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRX-2843 (a MER tyrosine kinase inhibitor) combined with osimertinib (Tagrisso)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced EGFR-mutant lung cancer whose disease has progressed on standard therapy.
What could go wrong: This is an early Phase 1b trial with only 69 participants, focused on safety and dosing. It may not show clear benefit, and side effects from the drug combination are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED LUNG NON-SMALL CELL CARCINOMA METASTATIC LUNG NON-SMALL CELL CARCINOMA STAGE IV LUNG CANCER AJCC V8 STAGE IVA LUNG CANCER AJCC V8 STAGE IVB LUNG CANCER AJCC V8

Contacts and locations

Locations

Emory University Hospital/Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.